NICE approves use of Adcetris for Hodgkin lymphoma.- Seattle Genetics.
UK NICE has approved the use of Adcetris (brentuximab), from Seattle Genetics, for patients with Hodgkin lymphoma who do not respond to chemotherapy. This funding approval is for use in patients with classical Hodgkin lymphoma whose disease returns after, or is resistant to, two types of chemotherapy and who are not able to undergo additional chemotherapy or a stem cell transplant. Adcetris has been available to this subset for patients in England for the past five years via the Cancer Drugs Fund.
Comment: NICE has already recommended Adcetris to treat CD30+ve R/R Hodgkin lymphoma following an ASCT (autologous stem cell transplantation).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.